3月3日 - ** 药物开发商BiohavenBHVN.N股价下跌4.1%，至35.66美元
** 根据伦敦证券交易所集团（LSEG）汇编的数据，该公司公布 (link)，第四季度每股亏损1.71美元，而分析师平均预期为亏损1.57美元。
** 另外，该公司表示， (link)，其实验性药物BHV-1300在一项早期研究中降低了84%的免疫球蛋白G（一种抗体），用于治疗一种名为巴塞杜氏病的自身免疫性疾病。
** 公司计划在 2025 年中期启动一项针对该病患者的中期研究
** BHVN 在过去 12 个月中下跌了 21.4
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.